Kenneth Riker

Juno Therapeutics, A Bristol-Myers Squibb Company

Over the last 16 years, Ken Riker has led Quality teams to develop and execute filing strategies for three successful global filings for biologics. Most recently he led the effort to evaluate the risk associated with the integrated control strategy for Bristol-Myers Squibb’s first cell therapy product. He lives in the Seattle area.